Precision medicine software company GenomOncology announced on Tuesday that it has partnered with WeTrials, an AI-powered patient engagement and trial enablement platform, to help central nervous system (CNS) cancer patients access and enrol in clinical trials faster.

This collaboration expands on the existing partnership between GenomOncology and Belay Diagnostics, creating a more complete pathway from molecular diagnosis to trial enrolment.

The initial phase of the partnership will focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types over time.

Alireza Mansouri, MD, co-founder and CMO of WeTrials, said: "We built WeTrials on the belief that clinical trials should never be the last resort, but a first consideration. When a clinician, or even a patient, can go directly from a genomic report to our platform, then pursue trial enrolment in a streamlined process, the barriers to enrolment drop significantly. Together with GenomOncology and Belay Diagnostics, we can ensure that molecular insights open the door to innovative therapies patients might otherwise never have known existed."